Minute Insights

Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.

The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.

Enovis has agreed to buy Italian orthopedic implant manufacturer Lima from a private equity firm for €800m – about $845m. The deal will expand Enovis’ presence in the fast-growing international extremities market and improve its manufacturing and innovation facilities.

The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.

The two tech companies – one software giant, the other focused on oncology – will work together on what will likely be the largest artificial intelligence model of its kind.

The genome-sequencing giant has named Jacob Thaysen, who brings extensive experience from Agilent, as its new leader.

The pure-play software company, which has developed a tool to record and monitor patients’ coughs, has signed a partnership to integrate its technology into a wearable.

The sequencing technology company, led by an interim CEO, is further shuffling its leadership following the announcement of disappointing mid-year results.

Cooper announced a plan to buy Cook’s reproductive health business in February. The deal would have been worth $675m up front and $200m in four annual installments. The US FTC determined the deal would have impaired competition in the reproductive health market.

Illumina sued Guardant last year, claiming Guardant’s founders stole trade secrets related to blood biopsy diagnostics. The companies have agreed to drop that dispute and share specimen samples for cancer research.

Surgalign was forced into bankruptcy after falling foul of the US SEC, leaving Audmedics to pick up its digital health assets for the bargain price of $900,000.

ViewRay will continue to maintain its MRI-guided radiation therapy systems at customer sites, but filed for Chapter 11 bankruptcy protection and is planning to sell the business’ assets.

Medtronic has secured coverage to market its recently approved MiniMed 780G insulin pump to eligible Medicare and Medicare Advantage beneficiaries, opening access to more patients after a long delay in bringing the device to the US market.